MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation |
|
|
| Recruiting | 3 | 1594 | Europe, Canada, US, RoW | Teclistamab, JNJ-64007957, Lenalidomide | Stichting European Myeloma Network, Janssen Pharmaceutica | Multiple Myeloma | 04/28 | 04/32 | | |
| Recruiting | 2 | 50 | Europe | Elranatamab | Stichting European Myeloma Network, Pfizer | Smoldering Multiple Myeloma | 07/27 | 07/31 | | |
| Recruiting | N/A | 6000 | Europe, RoW | storage of biological samples | Stichting European Myeloma Network, Janssen, LP | Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma, MGUS | 12/37 | 12/37 | | |